Cargando…
Current and Future Direct-Acting Antivirals Against COVID-19
The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed cases with a mortality rate of 2.6% globally....
Autor principal: | Chan, Shiu-Wan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688518/ https://www.ncbi.nlm.nih.gov/pubmed/33262747 http://dx.doi.org/10.3389/fmicb.2020.587944 |
Ejemplares similares
-
Directly Acting Antivirals for COVID-19: Where Do We Stand?
por: Teoh, Siew L., et al.
Publicado: (2020) -
The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses
por: Tse, Longping V., et al.
Publicado: (2020) -
Antiviral activity of zinc against hepatitis viruses: current status and future prospects
por: Kumar, Shiv, et al.
Publicado: (2023) -
Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021) -
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan
por: Khaliq, Saba, et al.
Publicado: (2018)